233P Association of quality of life (QOL) with overall survival (OS) in patients (pts) with HR+/HER2− advanced breast cancer (ABC) treated with ribociclib (RIB) + endocrine therapy (ET) in the MONALEESA-3 (ML-3) and ML-7 trials

Fasching, Peter A.; Harbeck, Nadia; Jérusalem, Guy; Colleoni, Marco; Neven, Patrick; Franke, F.; Laurentiis, Michelino De; Tripathy, Debu; Martín, Miguel; Babu, G. Suresh; Yardley, Denise A.; Wheatley‐Price, Paul; Chan, Arlene; Vázquez, Rafael; Nusch, Arndt; Gu, Ennan; Hu, Hao; Pathak, Purnima; Thuerigen, A.; Bardia, Aditya

doi:10.1016/j.annonc.2021.08.516

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… 54 Consistently, a pooled analysis including the overall population of the MONALEESA-3 trial and patients treated with ribociclib/placebo plus an NSAI in the MONALEESA-7 trial demonstrated a greater GHS improvement in patients with longer overall survival, especially among subjects receiving ribociclib. 55 Another pooled analysis of HR-QoL results was conducted in the whole population of the MONALEESA-2 study, in patients receiving ribociclib plus fulvestrant or placebo plus fulvestrant as first-line treatment in the MONALEESA-3 trial and in patients treated with ribociclib/placebo plus an NSAI in the MONALEESA-7 trial. In line with the result of the single studies, GHS and QoL were maintained throughout the treatment period to decline at the time of study discontinuation in both arms, whereas TTD of GHS, pain and emotional functioning was delayed in the ribociclib group.…”

Section: Resultsmentioning

confidence: 99%

Health-related quality of life in breast cancer patients treated with CDK4/6 inhibitors: a systematic review

Lauro¹,

Barchiesi²,

Martorana³

et al. 2022

ESMO Open

Self Cite

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Health-related quality of life in breast cancer patients treated with CDK4/6 inhibitors: a systematic review

Lauro¹,

Barchiesi²,

Martorana³

et al. 2022

ESMO Open

Self Cite

View full text Add to dashboard Cite

“…Однако в 2021 г. P. Fasching и соавт. опубликовали данные о том, что улучшение качества жизни по опроснику EORTC QLQ-C30 прямо коррелировало с долей пациентов, у которых отмечена более длительная ОВ [39]. Принимая во внимание положительные результаты исследования эффективности рибоциклиба, важно рассмотреть и качество жизни на фоне терапии [40].…”

Section: качество жизниunclassified

Antitumor response and quality of life: is there a need to sacrifice? Clinical observation: long-term and safe control of the disease using a combination of ribociclib with letrozole. Case report

Grechukhina

Vorontsova²,

Филоненко³

et al. 2022

J. Mod. Onco.

View full text Add to dashboard Cite

Metastatic luminal B HER2-negative breast cancer (HR+/HER2- mBC) occupies a leading place in the global structure of morbidity and mortality among women. The current gold standard of first-line treatment is the combination of CDK4/6 inhibitors with aromatase inhibitors, among which ribociclib with letrozole is distinguished. According to the MONALEESA-2 study, the addition of ribociclib to letrozole significantly increased the median overall survival to 63.9 months, reducing the risk of death by 24%. The safety profile of the combination is manageable, and the development of adverse events led to the interruption of therapy only in 7.5% of cases. A study of the actual clinical practice of CompLEEment-1 also confirmed the safety and effectiveness of the combination. Maintaining and improving the quality of life is one of the main tasks in the treatment of patients with HR+/HER2- mBC. According to the MONALEESA-2 study, the addition of ribociclib significantly affects the maintenance of quality of life and leads to a decrease in the intensity of pain syndrome. The published data allowed us to assign a combination of ribociclib and letrozole 4 points on the ESMO-MCBS scale. The safety of long-term use of the combination in the first line of treatment illustrated by clinical observation. The patient's progression-free survival during therapy was 40 months, which significantly exceeds the data of the MONALEESA-2 and CompLEEment-1 studies. The maximum effect (partial response according to RECIST 1.1 -40%) achieved after 24 weeks and persisted for 24 months. Clinically, the patient noted a decrease in the severity of the pain syndrome after 8 weeks of therapy. Against the background of therapy, it was possible to maintain the quality of life without sacrificing antitumor efficacy.

show abstract

“…Кроме того, усиление болевого синдрома, время до ухудшения эмоционального и социального функционирования по крайней мере на 10% при терапии рибоциклибом наступало позднее, чем на ГТ + плацебо. Авторы анализа делают вывод, что комбинированная терапия рибоциклибом и ГТ не только приводит к увеличению ОВ, но и значимо влияет на сохранение удовлетворительного качества жизни пациенток с люминальным HER2-отрицательным распространенным РМЖ [17].…”

Section: оценка качества жизни в клинических исследованиях Monaleesaunclassified

Quality of life and overall survival are primary priorities of patients with advanced breast cancer: results of sociological research

Kolomeytseva

Bokova²

2022

J. Mod. Onco.

View full text Add to dashboard Cite

Background. Breast cancer is the most common cancer in women. Metastatic breast cancer is an incurable disease, the main treatment goals of which are to increase overall survival and improve quality of life. Aim. To assess the priorities of patients with breast cancer in the framework of a sociological study. Materials and methods. For the first time, the main results of a sociological study of patients diagnosed with breast cancer, conducted by the Interregional Public Movement "Movement Against Cancer" in OctoberNovember 2021. This analysis reflects the needs of patients with breast cancer in various regions of the Russian Federation. A total of 675 people were interviewed,662 questionnaires were allowed for analysis. Results. In the rating of patients' desires regarding the results of treatment, regardless of the region and the duration of the course of the disease, the leading positions were taken by "improved quality of life" (46.2%) and "increased life expectancy" (46.4%). In the rating of preferences regarding the therapy received, the first place was taken by the value It is important to maintain good health, working capacity and the ability to live a full life (39.1%). Conclusion. The priority for all patients diagnosed with breast cancer is an effective and safe treatment that will ensure a good health and performance and safe a high quality of life for a long time.

show abstract

233P Association of quality of life (QOL) with overall survival (OS) in patients (pts) with HR+/HER2− advanced breast cancer (ABC) treated with ribociclib (RIB) + endocrine therapy (ET) in the MONALEESA-3 (ML-3) and ML-7 trials

Abstract: Association of quality of life (QOL) with overall survival (OS) in patients (pts) with HR+/HER2L advanced breast cancer (ABC) treated with ribociclib (RIB) + endocrine therapy (ET) in the MONALEESA-3 (ML-3) and ML-7 trials

Cited by 3 publications

References 0 publications

Health-related quality of life in breast cancer patients treated with CDK4/6 inhibitors: a systematic review

Health-related quality of life in breast cancer patients treated with CDK4/6 inhibitors: a systematic review

Antitumor response and quality of life: is there a need to sacrifice? Clinical observation: long-term and safe control of the disease using a combination of ribociclib with letrozole. Case report

Quality of life and overall survival are primary priorities of patients with advanced breast cancer: results of sociological research

Contact Info

Product

Resources

About